JP Morgan Upgrades NxStage Medical To Overweight, $26 PT

June 10, 2011 6:23 AM | 7 seconds read |
JP Morgan has upgraded NxStage Medical NXTM from Neutral to Overweight and maintains its $26 price target.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: UpgradesPrice TargetAnalyst RatingsHealth CareHealth Care EquipmentJP MorganNxStage Medical
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!